Business Monitor International


United Arab Emirates Pharmaceuticals & Healthcare Report

Published 16 July 2014

  • 122 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
United Arab Emirates Pharmaceuticals & Healthcare Report

BMI View: The UAE is one of the more developed markets in the Middle East and has a strong existing healthcare infrastructure. As the UAE is aiming to introduce comprehensive health insurance throughout the country , allowing businesses to shoulder much of the cost of this expanded coverage, the government will gradually contribute less to the country's healthcare spending. Between 2013 and 2018, we expect private sector healthcare spending to outpace public. However, the public sector will remain the main source of healthcare expenditure, contributing over 60% of total spending by 2023.

Headline Expenditure Projections:

  • Pharmaceuticals: AED7.02bn (USD1.91bn) in 2013 to AED7.44bn (USD2.03bn) in 2014; +6.0% in local currency and +6.1% in US dollar terms. Forecast in line with previous quarter.

  • Healthcare: AED42.60bn (USD11.60bn) in 2013 to AED45.82bn (USD12.48bn) in 2014; +7.6% in local currency terms and US dollar terms. Forecast revised down from previous quarter due to recently released WHO data.

Risk/Reward Rating

The UAE has moved up one place in our Pharmaceutical Risk/Reward Rating (RRR). In Q3 2014 it ranks third out of a total of 30 markets in the Middle East and Africa region, with a score of 57.4.

Key Trends & Developments

June

The UAE is among the first five countries in the Arab world to implement an updated and more stringent set of healthcare measures, which will be effective from July 1 2015, reports Gulf Today. The new measures will guarantee public health safety and benefits, in the midst of an increasing number of drugs and treatment methods flooding the market. The main aim is to ensure that all pharmaceutical products entering the region are safe and effective, so that the increasing incidence of disease is mitigated. May

The UAE's health ministry announced that rotavirus vaccination is mandatory for all babies in the country, reports the National. The vaccine, which protects against the deadly virus that causes gastroenteritis,...

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (United Arab Emirates 2010-2018)
17
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (United Arab Emirates 2010-2018)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (United Arab Emirates 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (United Arab Emirates 2010-2018)
20
Prescription Drug Market Forecast
20
Table: UAE Healthcare Demand Split By Therapeutic Area
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (United Arab Emirates 2010-2018)
23
Patented Drug Market Forecast
24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (United Arab Emirates 2010-2018)
25
Generic Drug Market Forecast
25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (United Arab Emirates 2010-2018)
27
OTC Medicine Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (United Arab Emirates 2010-2018)
28
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (United Arab Emirates 2012-2018)
30
Table: Pharmaceutical Trade Data And Forecasts local currency (United Arab Emirates 2012-2018)
31
Other Healthcare Data
31
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
34
Fiscal Position Remains Solid
36
Non-Oil Sector To Become Growth Driver
38
Table: United Arab Emirates - Economic Activity
39
Industry Risk Reward Ratings
40
Middle East & Africa Risk/Reward Ratings
40
United Arab Emirates Risk/Reward Ratings
48
Rewards
48
Risks
49
Market Overview
50
Industry Trends And Developments
52
Epidemiology
52
Table: UAE Healthcare Demand Split By Therapeutic Area
53
Healthcare Sector
57
Healthcare Sector Developments
59
Health Insurance
64
Research & Development
69
Regulatory Development
71
Regulatory Regime
71
Regulatory Developments
72
Pharmacovigilance
73
Pharmaceutical Advertising
73
Intellectual Property Issues
74
Pricing Regime
77
Pricing And Reimbursement Developments
78
Regional Harmonisation
80
Competitive Landscape
83
Pharmaceutical Sector
83
Table: Abu Dhabi's Top Five Best Selling Drugs In Value Terms By Therapeutic Area
83
Domestic Industry
84
Foreign Industry
86
Recent Company Developments
87
Pharmaceutical Distribution And Retail
88
Recent Developments
89
Company Profile
90
Gulf Pharmaceutical Industries (Julphar)
90
Modern Pharmaceutical Company
94
Neopharma
96
Medpharma
100
GlaxoSmithKline
102
Pfizer
104
Novartis
106
Johnson & Johnson
108
Sanofi-Aventis
110
Abbott Laboratories
112
Merck & Co
114
Demographic Forecast
116
Table: United Arab Emirates' Population By Age Group, 1990-2020 ('000)
117
Table: United Arab Emirates' Population By Age Group, 1990-2020 (% of total)
118
Table: United Arab Emirates' Key Population Ratios, 1990-2020
119
Table: United Arab Emirates' Rural And Urban Population, 1990-2020
119
Glossary
120
Methodology
122
Pharmaceutical Expenditure Forecast Model
122
Healthcare Expenditure Forecast Model
122
Notes On Methodology
123
Risk/Reward Ratings Methodology
124
Ratings Overview
125
Table: Pharmaceutical Risk/Reward Ratings Indicators
125
Indicator Weightings
126

The United Arab Emirates Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's United Arab Emirates Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Emirati pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for United Arab Emirates to test other views - a key input for successful budgeting and strategic business planning in the Emirati pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Emirati pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in United Arab Emirates.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc